Vnitr Lek 2014, 60(5-6):484-489

Sentinel lymph node in malignant melanoma

Eva Rovenská
Klinika chirurgickej onkológie Slovenskej zdravotníckej univerzity a Národného onkologického ústavu Bratislava, Slovenská republika, prednosta prof. MUDr. Juraj Pechan, CSc.

Melanoma is highly malignant tumor which arises through malignant transformation of melanocytes. Surgical treatment of primary cutaneous melanoma including radical excision and intervention in regional lymphatic drainage is irreplaceable. Sentinel node biopsy is a recognized method of defining the stage of disease. Performance of sentinel node biopsy in patients in clinical stage Ib and II may reveal clinically occult nodal disease and thereby help identify a group of patients with occult stage III disease who may thereafter undergo complete lymphadenectomy and systemic treatment. Sentinel node biopsy is beneficial in treatment of melanoma, but the therapeutic value of sentinel node biopsy is still not completely clear and remains disputable.

Keywords: melanoma; sentinel lymph node; sentinel node biopsy

Received: February 21, 2014; Accepted: March 21, 2014; Published: May 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rovenská E. Sentinel lymph node in malignant melanoma. Vnitr Lek. 2014;60(5-6):484-489.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Krajsová I. Melanom. Maxdorf: Praha 2006. ISBN 80-7345-096-8.
    2. Garbe C, Peris K, Hauschild A et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline-update 2012. Eur J Cancer 2012; 48(15): 2375-2390. Go to original source... Go to PubMed...
    3. Mervic L. Prognostic factors in patients with localized primary cutaneous melanoma. Acta dermatovenerol Alp Panonica Adriat 2012; 21(2): 27-31.
    4. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27(36): 6199-6206. Go to original source... Go to PubMed...
    5. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19(16): 3635-3648. Go to original source... Go to PubMed...
    6. Sekula-Gibbs SA, Shearer MA Sentinel node biopsy should be offered in thin melanoma with mitotic rate greater than one. Dermatol Surg 2011; 37(8): 1080-1088. Go to original source... Go to PubMed...
    7. Wong SL, Balch CM, Hurley P et al. Sentinel lymph node biopsy for melanoma: American society of clinical oncology and society of surgical oncology joint clinical practice guideline. J Clin Oncol 2012; 30(23): 2912-2918. Go to original source... Go to PubMed...
    8. Mocellin S, Pasquali S, Nitti D. The impact of surgery on survival of patients with cutaneous melanoma. Revisiting the role of primary tumor excision margins. Ann Surg 2011; 253(2): 238-243. Go to original source... Go to PubMed...
    9. Anderson KC, Alsina M, Bensinger W. Multiple myeloma, version 1.2013. J Natl Compr Canc Netw 2013; 11(1): 11-17. Go to original source... Go to PubMed...
    10. Grotz TE, Glorioso JM, Pockaj BA et al. Preservation of the deep muscular fascia and locoregional control in melanoma. Surgery 2013; 153(4): 535-541. Go to original source... Go to PubMed...
    11. Benca J, Rovenská E, Karaba M. Chirurgická terapia malígneho melanómu. Onkológia 2013; 8(3): 156-158.
    12. Grotz TE, Markovic SN, Erickson LA et al. Mayo clinic consensus recommendations for the depth of excision in primary cutaneous melanoma. Mayo Clin Proc 2011; 86(6): 522-528. Go to original source... Go to PubMed...
    13. Olsen G. Removal of fascia - cause of more frequent metastases of malignant melanomas of the skin to regional lymph nodes? Cancer 1964; 17: 1159-1164. Go to original source...
    14. Hlavatá Z. Čaká nás "nová éra" v malígnom melanóme? Onkológia 2011; 6(5): 282-285.
    15. Morton DL. Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis 2012; 29(7): 699-706. Go to original source... Go to PubMed...
    16. Morton DL, Thompson JF, Essner R et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg 1999; 230(4): 453-463. Go to original source... Go to PubMed...
    17. Morton DL, Wen DR, Wong JH et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127(4): 392-399. Go to original source... Go to PubMed...
    18. Balch CM, Morton DL, Gershenwald JE et al. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol 2009; 60(5): 872-875. Go to original source... Go to PubMed...
    19. Šimša J et al. Sentinelová uzlina. Lymfadenektomie u solidních nádorů. Maxdorf: Praha 2010. ISBN 978-80-7345-213-1.
    20. Fait V, Chrenko V, Gatěk J et al. Biopsie sentinelové uzliny u kožních nádorů. In: Neoral Č, Bohanes T et al. Biopsie sentinelové uzliny. Galén: Praha 2012. ISBN 978-80-7262-882-7.
    21. Baldwin BT, Cherpelis BS, Sondak V et al. Sentinel lymph node biopsy in melanoma: facts and controversies. Clin Dermatol 2010; 28(3): 319-323. Go to original source... Go to PubMed...
    22. Stebbins WG, Garibyan L, Sober AJ. Sentinel lymph node biopsy and melanoma: 2010 update Part II. J Am Acad Dermatol 2010; 62(5): 737-748. Go to original source... Go to PubMed...
    23. Gauwerky KJ, Kunte C, Geimer T et al. The outcome of patients with melanoma is not associated with the time point of lymphatic mapping with respect to excisional biopsy of the primary tumor. Dermatology 2010; 220(4): 355-362. Go to original source... Go to PubMed...
    24. Karakousis CP, Grigoropoulos P. Sentinel node biopsy before and after wide excision of the primary melanoma. Ann Surg Oncol 1999; 6(8): 785-789. Go to original source... Go to PubMed...
    25. McCready DR, Ghazarian DM, Hershkop MS et al. Sentinel lymph-node biopsy after previous wide local excision for melanoma. Can J Surg 2001; 44(6): 432-434.
    26. Chakera AH, Hansen LB, Lock-Andersen J et al. In-transit sentinel nodes must be found: implication from a 10-year follow-up study in melanoma. Melanoma Res 2008; 18(5): 359-364. Go to original source... Go to PubMed...
    27. Ortín-Pérez J, Vidal-Sicart S, Doménech B et al. In-transit sentinel lymph nodes in malignant melanoma. What is their importance? Rev Esp Med Nucl 2008; 27(6): 424-429. Go to original source... Go to PubMed...
    28. Lens M. Sentinel lymph node biopsy in melanoma patients. J Eur Acad Dermatol Venereol 2010; 24(9): 1005-1012. Go to original source... Go to PubMed...
    29. Badgwell BD, Pierce C, Broadwater JR et al. Intraoperative sentinel lymph node analysis in melanoma. J Surg Oncol 2011; 103(1): 1-5. Go to original source... Go to PubMed...
    30. Koopal SA, Tiebosch AT, Albertus Piers D et al. Frozen section analysis of sentinel lymph nodes in melanoma patients. Cancer 2000; 89(8): 1720-1725. Go to original source...
    31. Starz H. Pathology of the sentinel lymph node in melanoma. Semin Oncol 2004; 31(3): 357-362. Go to original source... Go to PubMed...
    32. Scolyer RA, Murali R, McCarthy SW et al. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol 2008; 25(2): 100-111. Go to original source... Go to PubMed...
    33. Scolyer RA, Murali R, Satzger I et al. The detection and significance of melanoma micrometastases in sentinel nodes. Surg Oncol 2008; 17(3): 165-174. Go to original source... Go to PubMed...
    34. Bogenrieder T, van Dijk MR, Blokx WAM et al. No non-sentinel node involvement in melanoma patients with limited Breslow thickness and low sentinel node tumour load. Histopathology 2011; 59(2): 318-326. Go to original source... Go to PubMed...
    35. Cook MG, Green MA, Anderson B et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 2003; 200(3): 314-319. Go to original source... Go to PubMed...
    36. Stebbins WG, Garibyan L, Sober AJ. Sentinel lymph node biopsy and melanoma: 2010 update Part I. J Am Acad Dermatol 2010; 62(5): 723-734. Go to original source... Go to PubMed...
    37. Shivers S, Jakub J, Pendas S et al. Molecular staging for patients with malignant melanoma. Expert Rev Anticancer Ther 2007; 7(11): 1665-1674. Go to original source... Go to PubMed...
    38. Romanini A, Manca G, Pellegrino D et al. Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome. Ann Oncol 2005; 16(11): 1832-1840. Go to original source... Go to PubMed...
    39. Garbe C, Eigentler TK, Bauer J et al. Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: review of the literature and recommendations for general practice. J Dtsch Dermatol Ges 2011; 9(9): 690-699. Go to original source... Go to PubMed...
    40. Piris A, Mihm jr. MC, Duncan LM. AJCC melanoma staging update: impact on dermatopathology practice and patient management. J Cutan Pathol 2011; 38(5): 394-400. Go to original source... Go to PubMed...
    41. Johnson T, Sondak VK, Bichakjian CK et al. The role of sentinel lymph node biopsy for melanoma: Evidence assessment. J Am Acad Dermatol 2006; 54(1): 19-27. Go to original source... Go to PubMed...
    42. Gershenwald JE, Soong SJ, Balch CM. 2010 TNM staging system for cutaneous melanoma...and beyond. Ann Surg Oncol 2010; 17(6): 1475-1477. Go to original source... Go to PubMed...
    43. Balch CM, Gershenwald JE, Soong SJ et al. Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010; 28(14): 2452-2459. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.